ArticleScientific reports2025
Optimizing the therapeutic benefits of synriam combined with praziquantel in mice harbouring juvenile and mature Schistosoma mansoni.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antischistosomal Ozonide Glycine Ethyl Esters.ACS medicinal chemistry letters · 2026Article
- N- and O‑Prenylated Quinolones: Syntheses andACS medicinal chemistry letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schistosomiasis, a prevalent tropical disease, possess public health challenges, with the standard treatment, praziquantel (PZQ), facing some limitations. Synriam (SYN), an antimalarial medication, has showed promises against schistosomiasis, although in vivo research on its efficacy in preventing infection-related consequences has not been thoroughly explored. This study looked at the effectiveness of SNY-PZQ combination treatment against Schistosoma mansoni in mice at various developmental phases, including juvenile (schistosomula) and mature stages. Worm load, egg deposition, parasite maturity, and liver histology were among the key outcomes evaluated. Their modulatory effects on liver injury indicators, proinflammatory cytokines, CYP450 enzymes, and apoptosis in mice infected with mature S. mansoni were also investigated. The study was divided into two experimental batches: schistosomula and mature stages, with infected mice from each batch divided into five groups to evaluate SNY, PZQ, and their combination. The SNY-PZQ combination was administered 3 weeks post-infection (PI) for schistosomula-stage infection, and 7 weeks PI for mature-stage infection. When SYN is combined with PZQ in their sub-curative doses (SC), it strengthens the worm killing effects, making it more potent than giving PZQ alone (SC), especially when the dual treatment was given against 7-weeks mature worms (95% vs. 76% for PZQ SC). This was accompanied with almost total eggs elimination and the repair of hepatic granulomatous lesions. Nevertheless, this combination therapy has moderate effectiveness (47% vs. 13% for PZQ SC) when given against 3-weeks juvenile worms. Furthermore, administering this combined therapy to 7-weeks mature worms reduces liver damage as evidenced by decreased oxidative stress, inflammation, and apoptosis, as well as normalization of liver serum enzymes, when compared to PZQ alone, implying that they may contribute to liver fibrosis prevention. Overall, SYN, when combined with PZQ, could improve treatment efficacy, potentially overcoming drug failures, offering a cost-effective strategy for managing schistosomiasis in resource-limited countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.